GLIADEL Drug Patent Profile
✉ Email this page to a colleague
When do Gliadel patents expire, and when can generic versions of Gliadel launch?
Gliadel is a drug marketed by Azurity and is included in one NDA.
The generic ingredient in GLIADEL is carmustine. There are eleven drug master file entries for this compound. Twelve suppliers are listed for this compound. Additional details are available on the carmustine profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Gliadel
A generic version of GLIADEL was approved as carmustine by NAVINTA LLC on September 11th, 2018.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for GLIADEL?
- What are the global sales for GLIADEL?
- What is Average Wholesale Price for GLIADEL?
Summary for GLIADEL
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 106 |
Clinical Trials: | 45 |
Patent Applications: | 5,086 |
Drug Prices: | Drug price information for GLIADEL |
What excipients (inactive ingredients) are in GLIADEL? | GLIADEL excipients list |
DailyMed Link: | GLIADEL at DailyMed |
Recent Clinical Trials for GLIADEL
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Michele Aizenberg, MD | Phase 2 |
Arbor Pharmaceuticals, Inc. | Phase 2 |
M.D. Anderson Cancer Center | Phase 1/Phase 2 |
Pharmacology for GLIADEL
Drug Class | Alkylating Drug |
Mechanism of Action | Alkylating Activity |
US Patents and Regulatory Information for GLIADEL
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Azurity | GLIADEL | carmustine | IMPLANT;INTRACRANIAL | 020637-001 | Sep 23, 1996 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for GLIADEL
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Azurity | GLIADEL | carmustine | IMPLANT;INTRACRANIAL | 020637-001 | Sep 23, 1996 | ⤷ Sign Up | ⤷ Sign Up |
Azurity | GLIADEL | carmustine | IMPLANT;INTRACRANIAL | 020637-001 | Sep 23, 1996 | ⤷ Sign Up | ⤷ Sign Up |
Azurity | GLIADEL | carmustine | IMPLANT;INTRACRANIAL | 020637-001 | Sep 23, 1996 | ⤷ Sign Up | ⤷ Sign Up |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
EU/EMA Drug Approvals for GLIADEL
Company | Drugname | Inn | Product Number / Indication | Status | Generic | Biosimilar | Orphan | Marketing Authorisation | Marketing Refusal |
---|---|---|---|---|---|---|---|---|---|
medac Gesellschaft für klinische Spezialpräparate mbH | Carmustine medac (previously Carmustine Obvius) | carmustine | EMEA/H/C/004326 Carmustine is indicated n adults in the following malignant neoplasms as a single agent or in combination with other antineoplastic agents and/or other therapeutic measures (radiotherapy, surgery):, , , Brain tumours (glioblastoma, brain-stem gliomas, medulloblastoma, astrocytoma and ependymoma), brain metastases, Secondary therapy in non-Hodgkin’s lymphoma and Hodgkin’s disease, as conditioning treatment prior to autologous haematopoietic progenitor cell transplantation (HPCT) in malignant haematological diseases (Hodgkin’s disease / Non-hodgkin’s lymphoma)., , |
Authorised | yes | no | no | 2018-07-18 | |
>Company | >Drugname | >Inn | >Product Number / Indication | >Status | >Generic | >Biosimilar | >Orphan | >Marketing Authorisation | >Marketing Refusal |
International Patents for GLIADEL
See the table below for patents covering GLIADEL around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Denmark | 0476045 | ⤷ Sign Up | |
Canada | 2073561 | POLYANHYDRIDES D'ACIDES ALIPHATIQUES OLIGOMERISES INSATURATES (POLYANHYDRIDES OF THE OLIGOMERIZED UNSATURATED ALIPHATIC ACIDS) | ⤷ Sign Up |
Japan | 2626717 | ⤷ Sign Up | |
Norway | 940837 | ⤷ Sign Up | |
World Intellectual Property Organization (WIPO) | 9015586 | ⤷ Sign Up | |
>Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for GLIADEL
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
0260415 | SPC/GB01/013 | United Kingdom | ⤷ Sign Up | PRODUCT NAME: N,N'-BIS(2-CHLOROETHYL)-N-NITROSO-UREA (CARMUSTINE) COMBINED WITH A POLYANHYDRIDE HAVING A WEIGHT AVERAGE MOLECULAR WEIGHT OF GREATER THAN 20,000 PREPARED BY THE POLYCONDENSATION OF: (I) 4,4'-(TRIMETHYLENEDIOXY)-DIBENZOIC ACID; AND (II) SEBACIC ACID (POLI; REGISTERED: FR 561 907-5 19990105; UK PL 00012/0337 20000928 |
0260415 | C990036 | Netherlands | ⤷ Sign Up | PRODUCT NAME: CARMUSTINE; NAT. REGISTRATION NO/DATE: RVG 24056 19990809; FIRST REGISTRATION: FR 561 907-5 19981210 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |